Abstract
BACKGROUND: Lenvatinib with everolimus ('Len/Eve') is approved for advanced/metastatic RCC following one antiangiogenic therapy. OBJECTIVE: This study evaluated patient characteristics, treatment patterns and overall survival (OS) with second-line or later (2L+) Len/Eve for advanced/metastatic RCC. METHODS: A retrospective observational study was conducted using electronic health records. Adult patients who initiated 2L+ Len/Eve for advanced/metastatic RCC from May 13, 2016 to July 31, 2019 were included. Patient characteristics and treatment patterns were assessed across the overall population and by post-immuno-oncology (IO) and post-tyrosine kinase inhibitors (TKI) groups. OS was estimated from Len/Eve initiation (i.e., index date) using Kaplan-Meier. RESULTS: Among the study population (n=152), 44.1%received 2L/3L Len/Eve and median number of prior therapies was 3 (range:1-8). Median age was 63.2 years, 78.9%were Caucasian, 73.7%were male, and 56.6%had ECOG performance status 0/1. At initial diagnosis, 65.8%had stage IV disease. At index, 53.3%had an International Metastatic RCC Database Consortium risk score of intermediate/poor, 15.1%favorable, and 31.6%missing score. Sixty-five (42.8%) received IO-based regimens and 49.3%received TKIs directly before index. Median OS from index was 13.9 (95%CI: 9.5-16.5) months and 2L/3L and 4L+ were 12.1 (95%CI: 8.4-17.0) and 14.8 (95%CI: 8.9-22.5) months, respectively. Median OS for Len/Eve post-IO and post-TKI were 13.9 (95%CI: 8.4-21.3) and 14.8 (95%CI: 7.8-16.5) months, respectively. Conclusion: This study suggested that 2L+ Len/Eve has clinical effectiveness for advanced/metastatic RCC in a US community oncology setting. Future studies are needed to confirm the association of improved survival with 2L+ Len/Eve.
Original language | English (US) |
---|---|
Pages (from-to) | 189-197 |
Number of pages | 9 |
Journal | Kidney Cancer |
Volume | 5 |
Issue number | 4 |
DOIs | |
State | Published - 2021 |
Keywords
- Immuno-oncology
- clinical effectiveness
- non-clear cell
- overall survival
- tyrosine kinase inhibitors
ASJC Scopus subject areas
- Nephrology
- Oncology